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Introduction
Diabetes mellitus comprises a group of disorders 
that are characterised by elevated levels of 
plasma glucose which result in microvascular and 
macrovascular complications in the long term. The 
main pathophysiological defect in type 1 diabetes is 
pancreatic β-cell destruction and consequent insulin 
deficiency. The main defect in type 2 diabetes is often 
a combination of insulin resistance, together with 
relative or absolute insulin deficiency. Type 2 diabetes 
is by far the most common form of the disorder (it is nine 
times more common than type 1 diabetes mellitus). The 
World Health Organization (WHO) and the International 
Diabetes Federation (IDF) recognise it as a growing 
global epidemic.1 
Glycaemic control is central to diabetes management, 
as demonstrated in both the Diabetes Control and 
Complications Trial (DCCT) and the United Kingdom 
Prospective Diabetes Study, in which significant 
improvements in microvascular and, to a lesser extent, 
macrovascular complications were noted.2,3 Diabetes 
care is more complex, though, and there are multiple 
interventions beyond blood glucose control which can 
improve clinical outcomes.4 The American Diabetes 
Association (ADA) issues annual Clinical Practice 
Guidelines5 to address these interventions, and many 
diabetes societies around the world have endorsed 
the ADA guidelines, with a few minor changes. The 
generally recommended glycaemic target is glycated 
haemoglobin A1c (HbA1c) < 7%. This has target has been 
endorsed by The Society of Endocrinology Metabolism 
and Diabetes of South Africa (SEMDSA). Moreover, the 
European Society of Cardiology and the EASD have 
also recently issued revised guidelines and targets for 
cardiometabolic parameters in people with diabetes 
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Abstract
Objectives: The objective of this survey was to determine the therapeutic management of patients with diabetes 
in the South African private healthcare environment.
Design: The International Diabetes Management Practices Study is an international multicentre and observational 
study. In this paper, the local South African data from the cross-sectional cohort study are discussed. 
Setting: South African healthcare providers who were involved in the management of patients with diabetes.
Subjects: Subjects included male and female adult patients who were diagnosed with type 1 or type 2 diabetes 
mellitus and who consulted their healthcare provider during a specified period of two weeks.
Outcome measures: Information on patient demographic and socio-economic profiles, relevant medical histories, 
data on previous and concomitant antidiabetic treatments, glycaemic status, patient education levels and the 
impact of diabetes on absenteeism and hospitalisation was collected. 
Results: A total of 899 patients from 54 healthcare centres in South Africa participated. The mean age of patients 
in the study was 53.35 ± 14.47 years. The duration of diabetes was longer in type 1 diabetic patients. Of the type 
2 diabetic patients, 46.4% were on oral antidiabetic monotherapy and 44.1% on two oral medications. Metformin 
was the most commonly prescribed oral medication. Of the 242 patients with type 2 diabetes on insulin and oral 
combination, 175 were on one oral medication combined with insulin therapy. The mean haemoglobin A1c (HbA1c) 
of study participants was 8.2%.
Conclusion: These data demonstrate that in accordance with current global findings, the glycaemic control of 
the majority of a cohort of patients with diabetes managed in the private healthcare sector in South Africa was 
suboptimal when assessed according to HbA1c levels.
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with and without coronary artery disease (CAD).6 The 
most noteworthy recommendation relates to lipid 
parameters, in which the low-density lipoprotein (LDL) 
cholesterol target has been lowered. Individuals with 
type 2 diabetes mellitus who do not yet have CAD 
should have their LDL cholesterol lowered by 30-40% of 
their baseline values, while those with CAD should have 
their LDL cholesterol lowered to ≤ 1.8mmol/l.
Worldwide, a problem experienced in diabetes 
management is that, while guidelines and target levels 
relating to various clinical and metabolic parameters 
are widely published, these targets are often difficult 
to achieve in clinical practice. In the US, glycaemic 
control rates declined from 44.5% for the period 1988-
1994 to 35.8% for the period 1999-2000.7 
In South Africa, despite all these recommendations, a 
large number of patients are not well controlled, and 
do not reach the target HbA1c value of < 7%.
8-10 In striving 
to achieve glycaemic control, it is also important to 
minimise drug adverse events, such as hypoglycaemic 
episodes. Therefore, the best available treatment 
should be chosen to fit each individual patient’s needs. 
The aim of therapy is to achieve a level of glycaemic 
control that is associated with an acceptable level 
of side-effects and patient convenience, providing 
control without compromise.
Currently, there are no published data for the South 
African private healthcare sector that relate to 
diabetes management practices, or the success rates 
in achieving conventionally accepted management 
targets. Therefore, there is a need to assess current 
practices in diabetes management and to develop 
strategies to improve the quality of care for diabetes 
sufferers.
The International Diabetes Management Practices 
Study (IDMPS) is an international multicentre 
observational study which comprised two parts: a 
cross-sectional study to assess current practices in 
the management of subjects with type 1 and type 2 
diabetes mellitus, and a longitudinal study to evaluate 
all patients who were treated with insulin and to 
characterise insulin therapy.
In this paper, only the initial local South African data 
will be discussed, and then only data from the cross-
sectional cohort study. The primary objective of this part 
of the IDMPS study was to determine the therapeutic 
management of patients with type 2 diabetes in 
current medical practice. A secondary objective was 
to assess the therapeutic management of patients with 
type 1 diabetes.
Method
An international, noninterventional, multicentre, cross-
sectional survey of two weeks’ duration was conducted. 
In this study, each physician enrolled the first 10 patients 
with type 2 diabetes and the first five patients with type 
1 diabetes who visited him or her within the two-week 
study period. In the absence of a sufficient number of 
patients with type 1 diabetes, additional patients with 
type 2 diabetes could be enrolled.
To ensure that the participating physicians were rep-
resentative of the practitioners who manage patients 
with diabetes and who are experienced in insulin 
therapy (initiation and titration), a stratified sample 
was randomly drawn. The stratification was based on 
the speciality (endocrinologists, specialist physicians or 
general practitioners) and on the type of healthcare 
structure in the country. 
Patient selection
Male and female adult patients diagnosed with 
type 1 or type 2 diabetes mellitus who consulted 
their healthcare provider during the two weeks were 
asked for informed consent and invited to participate. 
Exclusion criteria included concomitant participation in 
a clinical trial and/or current temporary insulin therapy 
(gestational diabetes, pancreatic cancer and surgery).
Sample size determination
The sample size was determined on the basis of 
country, based on the primary objective, which was to 
assess the therapeutic management of patients with 
type 2 diabetes mellitus, and on the precision that was 
expected. Based on the assumption that insulin is the 
least prescribed therapy in terms of proportions, the 
sample size was determined in order to establish the 
frequency of patients who were treated with insulin.
The sample size was anticipated to give an estimation 
of proportions with an absolute precision of 20% and a 
confidence interval of 95%. 
The following calculation was used: 
n = p (1-p) x (1.96/e)²
n: per country sample size
p: estimated proportion of patients with type 2 diabetes mellitus who 
were treated with insulin
e: absolute precision (20%) x p = relative precision
Given this information, a computation table was built, 
which took into account the proportion of insulin 
treatments in all the prescriptions for patients with 
diabetes.
For example, if in a given country 10% of patients 
received insulin (p) with an absolute precision of 
20%, the sample size (number of patients with type 2 
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diabetes mellitus to be recruited) would be 864 patients 
in this country for each cross-sectional survey, as was 
the case in South Africa.
Data collection
Assessments were carried out on the occasion of 
a routine visit of a patient with diabetes to his or her 
treating physician, and included patient demographic 
and socio-economic profiles, relevant medical histories 
(including diabetic complications and co-morbidity 
factors), previous and concomitant antidiabetic 
treatments, glycaemic status, patient education 
levels and the impact of diabetes on absenteeism 
and hospitalisation. HbA1c was measured using the 
practitioner’s local laboratory only if historical data for 
HbA1c were not available for the preceding 12 months 
and if the practitioner did not intend requesting the test 
as part of his or her usual practice on the study day.
A printed data collection form was used for data 
collection.
Statistics
Data from all the participating centres in South Africa 
were combined and treated as one dataset for the 
purposes of the analysis. The statistical analysis was of a 
descriptive nature. Quantitative data were summarised 
by sample size, mean, median, standard deviation and 
minimum and maximum values. Qualitative data were 
summarised in frequency counts and percentages. 
The statistical analysis was performed by ClinStat, 
Pretoria, South Africa. All analyses were carried out on 
SAS®, Release 9.1.3, run under Microsoft® Windows® XP.
Ethics
The survey was conducted according to the principles 
laid down in the 18th World Medical Assembly (Helsinki, 
1964) and all subsequent amendments, and in 
accordance with the guidelines for good clinical 
practice. Ethics approval for the study was obtained 
from Pharma-Ethics. Written informed consent was 
obtained from all the participating patients.
Results
A total of 899 patients from 54 centres in South Africa 
were entered into the survey. The minimum number 
of recruited patients by a centre was three, and the 
maximum number that was recruited was 31. All 
patients who participated in the study complied with 
all the inclusion and exclusion criteria. 
The baseline demographic information of the 
participating patients is summarised in Table I as 
percentages or mean values.
The mean age of patients in the study was 53.35 ± 14.47 
years, and patients with type 1 diabetes were younger 
(39.05 ± 15.17 years) than patients with type 2 diabetes 
(57.4 ± 11.39 years). Figure 1 reflects the age distribution 
of the participating patients.
Most of the participating patients in the IDMPS were 
from urban areas. Only 5.9% were from rural areas.
A positive family history of diabetes mellitus was noted 
in 60% of type 2 subjects, and surprisingly in 46% of type 
1 subjects. However, no information was available 
regarding the type of diabetes in family members.
The waist circumference values are reflected as means 
without differentiation in the different ethnic groups, as 
the majority of the population used the cut-off value of 
< 80 cm in female patients and < 94 cm in male patients, 
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Figure 1: Age distribution of participating patients
Table I: Baseline demographic information
Demographics Type 1 Type 2 Total
Number of patients 198 701 899
Age in years [mean 
(SD)] 39.1 (15.2) 57.4 (11.4) 53.4 (14.5)
Gender (male, %) 56.1 56.1 56.1
Urban (%) 94.4 94 94.1
Positive family history of 
diabetes (%) 46.1 60.4 57.2
Waist circumference in cm [mean (SD)] 
Male 94.5 (15.3) 108.3 (14.3) 105.2 (15.6)
Female 86.5 (14) 101.7 (13.9) 98.5 (15.2)
Body mass index, kg/m2 [mean (SD)]
Male 27.1 (5.1) 31 (5.6) 30.1 (5.7)
Female 26.3 (5.6) 32.7 (6.8) 31.3 (7.1)
Systolic blood pressure 
in mmHg [mean (SD)] 125.9 (15.5) 132.9 (17.5) 131.4 (17.3)
Diastolic blood pressure 
in mmHg [mean (SD)] 77.4 (10.2) 80 (10.2) 79.4 (10.2)
Diagnosed with 
hypertension (%) 37.9 77.6 68.8
Diagnosed with 
dyslipidaemia (%) 40.3 62.3 57.5
Smokers (%)
Male 25.2 17.1 18.9
Female 16.3 7.2 9.2
SD: standard deviation
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The smoking status of patients who quit smoking was 
also collected. This was an additional 16.2% of male 
patients and 4.6% of female patients in the type 1 
diabetic patient group. In the type 2 diabetic patient 
group, quitters constituted an additional 25.6% of male 
patients and 8.2% of female patients. 
The race distribution according to the study’s definition 
of the patients entered in the survey is documented in 
Table II. Patients of mixed ethnic ancestry (so-called 
“coloured” patients) were included in the category of 
“other” ethnic groups. 
Table II: Race distribution
Race Number (%) of patients
Black 199 (22.1)
Caucasian 489 (54.5)
Oriental, Arab, Persian 1 (0.1)
South Asian 38 ( 4.2)
Other Asian 97 (10.8)
Other 75 (8.3)
Total 899 (100)
The duration of diabetes differed between the type 1 
and type 2 diabetes groups. Generally, type 1 diabetes 
had been present for longer in the studied groups. The 
distribution of the duration of diabetes is presented in 
Table III.
Table III: Distribution of the duration of diabetes
Duration of 
diabetes (years)
Number (%) of patients
Type 1 diabetes Type 2 diabetes
  1-1.9 3 (1.6) 32 (4.6)
  2-3.9 20 (10.5) 119 (17.2)
  4-5.9 12 (6.3) 97 (14.1)
  6-9.9 37 (19.4) 166 (24.1)
10-14.9 34 (17.8) 142 (20.6)
15-19.9 18 (9.4) 69 (10)
≥ 20 67 (35) 65 (9.4)
Total 191 (100) 690 (100)
The number of patients who received oral 
hypoglycaemic agents as part of their treatment 
regimen in this study population was 17.8% of patients 
with type 1 diabetes and 94.3% of patients with type 
2 diabetes. Of the patients with type 2 diabetes, 
46.4% were on monotherapy and 44.1% on two oral 
medications, while only 3.4% were on triple therapy. 
Metformin was the most commonly prescribed oral 
medication in all the patients. The different classes of 
medication used are represented in Table IV.
Table IV: Current classes of oral hypoglcaemic agents used by 
patients
Class Number (%) of patients
Type 1 diabetes Type 2 diabetes
Meglitinides – 9 (1.5)
Biguanides 23 (95.8) 527 (88.6)
Sulphonylureas 4 (16.7) 286 (48.1)




Other – 2 (0.3)
Of the 242 patients with type 2 diabetes on insulin and 
oral medication, 174 were on one oral medication 
combined with insulin therapy (71.9%). Sixty-six patients 
were taking two oral medications (27.3%) with their 
insulin therapy and two patients were using three oral 
medications and insulin therapy. 
HbA1c measurements were available for 96.4% of the 
patients. Most of the patients underwent an HbA1c test 
once or twice a year. The mean HbA1c of this study 
was 8.2% (median 7.8%). It was 8.8% (median 8.6%) in 
patients with type 1 diabetes, 8.1% (median 7.5%) in 
patients with type 2 diabetes.
The distribution of the most recent HbA1c values is 
depicted in Table V. A value was reported for only 
96.4% of patients. Thirty per cent of patients had an 
HbA1c value less than 7%, as defined as the target value 
according to guidelines. 
Table V: Distribution of the most recent haemoglobin A1c values
HbA1c value (%) Number (%) of patients






≥ 15 7 (0.8)
Total 867 (100)
Glycaemic control varied substantially when comparing 
the different treatment regimens in the patients with 
diabetes. The HbA1c was 7.62% in type 2 diabetic 
patients who were treated with oral medications only 
and 8.51% in those on oral medication and insulin 
therapy. This compares to an HbA1c of 9.02% in the 
insulin-only group. In evaluating the different insulin 
regimens in patients with type 2 diabetes, the basal 
insulin had an HbA1c of 8.25% only, the basal-prandial 
group’s an HbA1c of 8.71% and the premix insulin group 
an HbA1c of 8.66%.Table VI provides a summary of the 
effects of the treatment regimens of HbA1c levels. 
The most common indicated reasons by doctors for 
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HbA1c not being at target level were lack of compliance 
by the patient with lifestyle recommendations (29.5%) 
and the lack of efficacy of their current antidiabetic 
treatment (23.5%).
In this study, 321 (45.8%) of patients with type 2 diabetes 
were on insulin treatment as part of their management. 
These patients were analysed further according to the 
different types of insulin that they were taking. Table 
VII details patients’ different insulin treatment regimens 
and respective HbA1c values. All the patients with type 
2 diabetes who were on insulin were uncontrolled, with 
a mean HbA1c > 8%.
Discussion
The reflected data in this study are based on the 
information from healthcare providers in South Africa 
who prescribe insulin therapy. Therefore, this will not 
necessarily reflect the situation of all patients in South 
Africa, as these doctors probably manage their patients 
more aggressively than healthcare providers who do 
not prescribe insulin therapy. This study also reflects the 
information from patients in the South African private 
healthcare sector, about whom there has been very 
little available information in scientific publications.
The racial distribution is not representative of the total 
South African population, nor of the private healthcare 
population, but is rather indicative of the patients 
who visited the selected insulin-prescribing healthcare 
providers in South Africa.
The positive family history in approximately half of 
the patients with type 1 diabetes was very surprising. 
In future studies, it may be worthwhile to explore this 
further with regard to the specific type of diabetes of 
family members. It is also interesting that patients with 
type 2 diabetes had a positive family history in only 60% 
of cases. 
The data on waist circumference measurements 
in patients deserve comment. The mean waist 
circumference for both type 1 and type 2 diabetes 
patients was above the current IDF cutpoint (i.e. 
94cm for males and 80cm for females). As expected, 
patients with type 2 diabetes had a higher mean waist 
circumference, 102 cm for females and 108 cm for 
males. It is noteworthy that approximately 15% of the 
sample population comprised males of South Asian 
descent, for whom a lower cutpoint of 90 cm should 
be applied. These values highlight the importance 
of weight-loss therapy as part of the management 
of patients with diabetes. The importance of lifestyle 
therapy, in the form of nutritional advice and support 
and exercise participation according to specific 
patient needs, cannot be overstated. 
As can be expected, according to the healthcare 
providers who looked after these patients, 
approximately two-thirds of the patients with type 
2 diabetes had hypertension and dyslipidaemia. In 
contrast to data from elsewhere in the world, South 
African patients’ blood pressure was relatively well 
controlled. They had a mean systolic blood pressure 
of 131.4 mmHg and a mean diastolic blood pressure of 
79.4 mmHg.
Smoking remains a common problem in patients with 
diabetes in South Africa, as can be seen from these 
data. If the combined number of current and past 
Table VI: Treatment regimens with respective haemoglobin A1c values
Regimen Type 1 Type 2 All





Oral antidiabetic agents 
only
1 6.9 335 7.62 (1.87) 336 7.61 (1.87)
Insulin only 140 8.77 (1.95) 67 9.02 (2.33) 207 8.85 (2.08)
Insulin and oral agents 23 8.86 (2.08) 240 8.51 (1.82) 263 8.54 (1.84)
Table VII: Different insulin regimens with haemoglobin A1c values
Type 1 diabetes mellitus




Basal only 10 9.26 (2.45) 38.2 (16/60)
Basal and 
prandial 144 8.79 (1.88)
Basal: 27.28 (4/80)
Prandial: 29.8 (3/102)
Premix 30 9.11 (2.71) 45.83 (17/100)
Type 2 diabetes mellitus




Basal only 73 8.25 (1.88) 28.04 (4/96)
Basal and 
prandial 65 8.71 (1.8)
Basal: 31.43 (8/96)
Prandial: 32.62 (8/90)
Premix 176 8.66 (1.94) 49.66 (6/120)
All patients




Basal only 83 8.37 (1.97) 29.27 (4/96)
Basal and 
prandial 209 8.77 (1.85)
Basal: 28.57 (4/96)
Prandial: 30.67 (3/102)
Premix 206 8.72 (2.07) 49.11 (6/120)
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smokers is examined, this is definitely an area that may 
require more aggressive management if the mortality 
and morbidity of cardiovascular diseases is to be 
decreased. 
It is interesting to note that 29 of the 191 type 1 
diabetes patients were also taking oral antidiabetic 
medications in addition to their insulin treatment. These 
patients may represent a subgroup  of type 1 patients 
suspected of also having insulin resistance. This notion 
is supported by the elevated waist circumference in 
type 1 diabetes patients alluded previously. Hence, the 
additional oral medication may have been prescribed 
in an attempt to lower insulin requirements.12 One 
patient with type 1 diabetes on oral medication may 
have been a misclassification, as the patient seemed 
to be well controlled on the oral medication. This data 
set also demonstrates that prescribing triple therapy is 
not a common practice in South Africa, and that insulin 
initiation after failed dual medication therapy is more 
common.   
The reported HbA1c values were obtained from the 
practitioners’ usual source of laboratory testing. In 
the majority of cases, this was performed at either 
the Ampath or Lancet group of laboratories. These 
laboratories utilise different assay methods for glycated 
haemoglobin, but both are DCCT standardised and 
National Glycohemoglobin Standardization Program 
(NGSP) certified. However, the two methodologies 
do not yield identical results, and it is accepted that 
this may have affected the overall accuracy of the 
results. Notwithstanding the nonstandardised assay 
methodology for all subjects, the data accurately 
reflected the HbA1c values on which practitioners 
base their clinical decisions daily, and for this reason, 
the data remain relevant.
The data demonstrated that similar to the rest of 
the world, patients with diabetes in South Africa are 
not optimally controlled through evalution of their 
glycaemic control levels, as reflected by the HbA
1c 
levels. Only 30.4% of patients were well controlled and 
had HbA1c values < 7% (the target recommended by 
the SEMDSA guidelines at the time of the survey). This 
implies that 70% of patients were still not optimally 
controlled. From these data, it is clear that management 
of patients with diabetes is suboptimal and could still 
be improved. Patients who were treated with insulin 
reflected the worst glycaemic control, as assessed 
by HbA1c levels. This will need to be addressed by 
healthcare workers. If the different treatment regimens 
of the patients with type 2 diabetes are compared, it 
seems that the oral group had the best control. This is 
probably a reflection of the fact that type 2 diabetic 
patients who are in the early stages of the disease are 
on oral medication, while patients in the later stages 
of the disease are on insulin treatment. Based on these 
data, it seems that doctors are aware of the fact that 
they should prescribe insulin for patients timeously. It is 
clear from the data on patients with type 2 diabetes 
who were on insulin that patients’ insulin dosages were 
not titrated enough to achieve optimal control. The 
use of patient-driven dose optimisation in patients on 
insulin may be important to achieve target values in 
more patients who are being treated with insulin. 
Therefore, it is very important that all healthcare 
providers and their patients become more aware of 
the recommended target levels for glycaemic control 
according to guidelines, and that they strive to bridge 
the gap between the guidelines and practice.
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